Table 2.
Cause of death related to the day 28 response
| Severity of aGvHD prior to MSC-FFM | Treatment prior to MSC-FFM | CR (N = 22) | PR (N = 35) | NR (N = 10) | No report (N = 2) | Total | |
|---|---|---|---|---|---|---|---|
| TRM | |||||||
| Aspergillosis/candida | III/IV | SR/SR | 2 | 2 | |||
| Mucor | III/IV | SR/TR, 4 | 1 | 1 | 2 | ||
| Sepsis | III/IV | SR/TR, 3 | 1 | 1 | 2 | ||
| Virus/Adenovirus | IV/IV | TR, 5/TR, 4 | 2 | 2 | |||
| Cerebral haemorrague | IV | TR, 6 | 1 | 1 | |||
| GvHD | IV/IV/IV/IV | TR, 5/TR, 3/TR, 5/TR, 3 | 2 | 1 | 1 | 4 | |
| MOF | III/IV | TR, 5/ST | 2 | 2 | |||
| Acute abdomen due to strangulated hernia | III | ST | 1 | 1 | |||
| No data | IV | TR, 5 | 1 | 1 | |||
| Thrombembolism + HSV pneumonia | IV | TR, 3 | 1 | 1 | |||
| Relapse of the underlying disease | II/III/III | TR, 3/TR, 4/TR, 3 | 3 | 3 | |||
| Total | 6 (27%) | 8 (23%) | 5 (50%) | 2 (100%) | 21 (30%) | ||
Numbers after TR indicates the number of therapy lines used before the treatment with MSC-FFM
aGvHD acute graft-versus-host disease, CR complete response, PR partial response, NR non-response, TRM treatment related mortality, SR steroid refractory, TR treatment refractory, GvHD graft-versus-host disease, MOF multiple organ failure, HSV herpes simplex virus, MSC-FFM Mesenchymal Stromal Cell-Frankfurt am Main